In an earlier report we have shown that an allogeneic but not a syngeneic immunization of mice with lymphoma cells evoked a humoral complement-dependent cytotoxic response against lymphoma cells syngeneic with the serum. Here we report the results of an investigation, using the same experimental model, on the cellular antitumor response in vitro and the in vivo tumor resistance. Both the allogeneic and the syngeneic antitumor immunizations induced a cellular immune response that was detectable in vitro and that was not inhibited by the correspondent antiserum that was obtained with the same type of immunization. The humoral and cellular immune responses evoked in our system seem, therefore, directed against different antigenic determinants. In the in vivo experiments the maximal antitumor protection was obtained in mice immunized syngeneically, whereas the allogeneic immunization gave a protection that was similar to that obtained in mice immunized with normal allogeneic thymus cells. However, mitomycin-C-blocked thymus cells were unable to induce any protection against the tumor challenge, whereas blocked allogeneic tumor cells conferred the same degree of protection as that obtained with untreated cells. The in vivo transfer in untreated mice of sera obtained with syngeneic or allogeneic antitumor immunization did not give any protection against the tumor challenge.
Get full access to this article
View all access options for this article.
References
1.
BlankK. J., FreedmanH. A., LillyF.: T-lymphocyte response to Friend virus–induced tumor cell lines in mice of strain congenic at H-2. Nature, 260: 250–252, 1976.
2.
CerottiniJ. C., BrunnerK. T.: Cell-mediated cytotoxicity, allograft rejection and tumor immunity. Adv. Immunol., 18: 67–132, 1974.
3.
CollavoD., ParentiA., BiasiG., Chieco-BianchiL., ColombattiA.: Secondary in vitro generation of cytolytic T-lymphocytes (CTLs) in the murine sarcoma virus system. Virus-specific CTL induction across the H-2 barrier. J. Nat. Cancer Inst., 1978 (in press).
4.
ColnaghiM. I., Della PortaG.: Evidence for virus-related and unrelated antigens on murine lymphomas induced by chemical carcinogens. J. Nat. Cancer Inst., 50: 173–180, 1973.
5.
ColnaghiM. I.: Histocompatibility antigens acting as helper determinants for tumor-associated antigens of murine lymphosarcoma. Eur. J. Immunol., 5: 241–245, 1975.
6.
ColnaghiM. I., PierottiM. A., Della TorreG., MiottiS.: Antigen fluctuation and virus activation in EL4 cells transplanted in hybrid mice or cultured in vitro. J. Nat. Cancer Inst., 59: 123–130, 1977.
7.
DoellR. G., MathiesonB. J.: Serological studies of tumor antigens in chemical- and virus-induced thymic lymphomas. Cancer Res., 31: 1285–1289, 1971.
8.
FerrerJ. F., KaplanH. S.: Antigenic characteristics of lymphomas induced by radiation leukemia virus (RadLV) in mice and rats. Cancer Res., 28: 2522–2528, 1968.
9.
GomardE., DuprezV., RemeT., ColombaniM. J., LevyJ. P.: Exclusive involvement of H-2Db or H-2Kd product in the interaction between T-killer lymphocytes and syngeneic H-2b or H-2d viral lymphomas. J. Exp. Med., 146: 909–922, 1977.
10.
HannaM. G.Jr., TennantR. W., CogginJ. H.Jr.: Suppressive effect of immunization with mouse fetal antigens on growth of cells infected with Rauscher leukemia virus and on plasma-cell tumors. Proc. Nat. Acad. Sci. U.S.A., 68: 1748–1752, 1971.
11.
HayamiM., HellströmI., HellströmK. E., LanninD. R.: Further studies on the ability of regressor sera to block cell-mediated destruction of Rous sarcomas. Int. J. Cancer, 13: 43–53, 1974.
12.
HerbermanR. B., NunnM. E., LavrinD. H.: Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int. I. Cancer, 16: 216–229, 1975.
13.
HirschM. S., PhillipsS. M., SolnikC., BlackP. H., SchwartzR. S., CarpenterC. B.: Activation of leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro. Proc. Nat. Acad. Sci., U.S.A., 69: 1069–1072, 1972.
14.
IgelH. J., HuebnerR. J., TurnerH. C., KotinP., FalkH. L.: Mouse leukemia virus activation by chemical carcinogens. Science, 166: 1624–1626, 1969.
15.
KatzD. H., PaulW. E., GoidlE. A., BenacerrafB.: Carrier function in anti–hapten antibody responses. III. Stimulation of antibody synthesis and facilitation of hapten-specific secondary antibody responses by graft-versus-host reactions. J. Exp. Med., 133: 169–186, 1971.
16.
KatzD. H., PaulW. E., BenacerrafB.: Carrier function in anti-hapten antibody responses. V. Analysis of cellular events in the enhancement of antibody responses by the « allogeneic effect » in DNP-OVA-primed guinea pigs challenged with a heterologous DNP-conjugate. J. Immunol., 107: 1319–1328, 1971.
17.
KiesslingR., KleinE., WigzellH.: « Natural » killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. I. Immunol., 5: 112–117, 1975.
18.
KrethH. W., WilliamsonA. R.: Cell surveillance model for lymphocyte cooperation. Nature, 234: 454–456, 1971.
19.
McCullaghP. J.: The abrogation of sheep erythrocyte tolerance in rats by means of the transfer of allogeneic lymphocytes. J. Exp. Med., 132: 916–925, 1970.
20.
NabholzM., VivesJ., YoungH. M., MeoT., MiggianoV., RijnbeekA., ShrefflerD. C.: Cell-mediated cell lysis in vitro: genetic control of killer cell production and target specificities in the mouse. Eur. J. Immunol., 4: 378–387, 1974.
21.
PasternakG., PasternakL., MicheelB.: Antigenic conversion by leukemia viruses. pp. 155–169. In: RNA Viruses and Host Genome in Oncogenesis.EmmelotP., BentvelzenP. (eds.), North-Holland, Amsterdam, 1972.
22.
PierottiM. A., ColnaghiM. I.: Natural antibodies directed against murine lymphosarcoma cells. J. Nat. Cancer Inst., 55: 945–949, 1975.
23.
PierottiM. A., ColnaghiM. I.: Natural antibodies directed against murine lymphosarcoma cells: variability of level in individual mice. Int. J. Cancer, 18: 223–229, 1976.
24.
PlataF., JongeneelV., CerottiniJ. C., BrunnerK. T.: Antigenic specificity of cytolytic T-lymphocyte (CTL) response to murine sarcoma virus induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells. Eur. J. Immunol., 6: 823–829, 1976.
25.
PrehnR. T., LappeM. A.: An immunostimulation theory of tumor development. Transplant. Rev., 7: 26–54, 1971.
26.
SchraderJ. W., CunninghamB. A., EdelmanG. M.: Functional interactions of viral and histocompatibility antigens at tumor cell surfaces. Proc. Nat. Acad. Sci. U.S.A., 72: 5066–5070, 1975.
27.
ShearerW. T., PhilpottG. W., ParkerC. W.: Humoral immunostimulation. I. Increase uptake of [125I]iododeoxyuridine and [3H]thymidine into TNP-cells treated with anti-TNP antibody. J. Exp. Med., 139: 367–379, 1974.
28.
StonehillE. H., BendichA.: Retrogenetic expression: the reappearance of embryonal antigens in cancer cells. Nature, 228: 370–372, 1970.
29.
TingC. C., HerbermanR. B.: Specific afferent interference by antiserum of in vivo immunity. Nature, 257: 801–802, 1975.
30.
TingC. C., LawL. W.: Studies of H-2 restriction in cell-mediated cytotoxicity and transplantation immunity to leukemia-associated antigens. J. Immunol., 118: 1259–1264, 1977.
31.
WigzellH., SundqvistK. G., YoshidaT.O.: Separation of cells according to surface antigens by the use of antibody-coated columns. Fractionation of cells carrying immunoglobulins and blood group antigen. Scand. J. Immunol., 1: 75–87, 1972.
32.
ZinkernagelR. M., DohertyP. C.: Immunological surveillance against altered self component by sensitized T lymphocytes in lymphocytic choriomeningitis. Nature, 251: 547–548, 1974.
